FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011012011> ?p ?o ?g. }

• W2011012011 endingPage "135" @default.
• W2011012011 startingPage "125" @default.
• W2011012011 abstract "Abstract BACKGROUND The optimal management of patients with splenic marginal zone lymphoma/marginal zone lymphoma (SMZL) is controversial. The objective of this retrospective study was to compare the outcomes of patients with SMZL who received treatment with rituximab, rituximab plus chemotherapy, or chemotherapy alone. METHODS The Leukemia Service database was searched for patients with splenic lymphoma who were registered between May 1995 and October 2004. The indications for treatment were the same as those used for patients with chronic lymphocytic leukemia. RESULTS SMZL was confirmed in 70 patients. The median age was 64 years. The median number of CD20 molecules per cell was 69 × 10 3 . Forty‐three patients required systemic therapy; rituximab in 26 patients, chemotherapy plus rituximab in 6 patients, and chemotherapy alone in 11 patients. Ten additional patients underwent splenectomy, and 17 patients were in the observation group. The overall response rates were 88% with rituximab, 83% with rituximab plus chemotherapy, and 55% with chemotherapy alone; the 3‐year survival rates were 95%, 100%, and 55%, respectively. The 3‐year failure‐free survival (FFS) rates were 86%, 100%, and 45% in the rituximab, rituximab plus chemotherapy, and chemotherapy alone groups, respectively. Rituximab treatments resulted in longer survival and FFS compared with chemotherapy. Rituximab alone resulted in disappearance of splenomegaly in 92% of patients and normalization of absolute lymphocyte counts. In univariate analysis, younger age and rituximab‐based therapy were predictive of longer FFS. CONCLUSIONS Rituximab with or without chemotherapy was found to have major activity in patients with SMZL. These results may be associated with high levels of cellular CD20 antigen sites. Rituximab should be the treatment of choice, at least in older patients with SMZL who have comorbid diseases. Cancer 2006. © 2006 American Cancer Society." @default.
• W2011012011 created "2016-06-24" @default.
• W2011012011 creator A5006104041 @default.
• W2011012011 creator A5027575595 @default.
• W2011012011 creator A5035354255 @default.
• W2011012011 creator A5040146877 @default.
• W2011012011 creator A5044840107 @default.
• W2011012011 creator A5049662911 @default.
• W2011012011 creator A5051208373 @default.
• W2011012011 creator A5061026876 @default.
• W2011012011 creator A5067751550 @default.
• W2011012011 creator A5089428686 @default.
• W2011012011 creator A5090435894 @default.
• W2011012011 date "2006-05-12" @default.
• W2011012011 modified "2023-10-18" @default.
• W2011012011 title "Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone" @default.
• W2011012011 cites W138963765 @default.
• W2011012011 cites W1594564120 @default.
• W2011012011 cites W1912693401 @default.
• W2011012011 cites W1980559481 @default.
• W2011012011 cites W1985562916 @default.
• W2011012011 cites W1991142419 @default.
• W2011012011 cites W1993780590 @default.
• W2011012011 cites W1999670881 @default.
• W2011012011 cites W2014109120 @default.
• W2011012011 cites W2023506702 @default.
• W2011012011 cites W2026784737 @default.
• W2011012011 cites W2031737309 @default.
• W2011012011 cites W2045970616 @default.
• W2011012011 cites W2065947799 @default.
• W2011012011 cites W2075053994 @default.
• W2011012011 cites W2085286786 @default.
• W2011012011 cites W2097340977 @default.
• W2011012011 cites W2101499680 @default.
• W2011012011 cites W2104459071 @default.
• W2011012011 cites W2120543953 @default.
• W2011012011 cites W2120680699 @default.
• W2011012011 cites W2125134816 @default.
• W2011012011 cites W2139878655 @default.
• W2011012011 cites W2147979002 @default.
• W2011012011 cites W2160378262 @default.
• W2011012011 cites W2163790170 @default.
• W2011012011 cites W2165775167 @default.
• W2011012011 cites W2424729107 @default.
• W2011012011 cites W60865865 @default.
• W2011012011 doi "https://doi.org/10.1002/cncr.21931" @default.
• W2011012011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16700034" @default.
• W2011012011 hasPublicationYear "2006" @default.
• W2011012011 type Work @default.
• W2011012011 sameAs 2011012011 @default.
• W2011012011 citedByCount "116" @default.
• W2011012011 countsByYear W20110120112012 @default.
• W2011012011 countsByYear W20110120112013 @default.
• W2011012011 countsByYear W20110120112014 @default.
• W2011012011 countsByYear W20110120112015 @default.
• W2011012011 countsByYear W20110120112016 @default.
• W2011012011 countsByYear W20110120112017 @default.
• W2011012011 countsByYear W20110120112018 @default.
• W2011012011 countsByYear W20110120112019 @default.
• W2011012011 countsByYear W20110120112020 @default.
• W2011012011 countsByYear W20110120112021 @default.
• W2011012011 countsByYear W20110120112022 @default.
• W2011012011 countsByYear W20110120112023 @default.
• W2011012011 crossrefType "journal-article" @default.
• W2011012011 hasAuthorship W2011012011A5006104041 @default.
• W2011012011 hasAuthorship W2011012011A5027575595 @default.
• W2011012011 hasAuthorship W2011012011A5035354255 @default.
• W2011012011 hasAuthorship W2011012011A5040146877 @default.
• W2011012011 hasAuthorship W2011012011A5044840107 @default.
• W2011012011 hasAuthorship W2011012011A5049662911 @default.
• W2011012011 hasAuthorship W2011012011A5051208373 @default.
• W2011012011 hasAuthorship W2011012011A5061026876 @default.
• W2011012011 hasAuthorship W2011012011A5067751550 @default.
• W2011012011 hasAuthorship W2011012011A5089428686 @default.
• W2011012011 hasAuthorship W2011012011A5090435894 @default.
• W2011012011 hasBestOaLocation W20110120111 @default.
• W2011012011 hasConcept C126322002 @default.
• W2011012011 hasConcept C141071460 @default.
• W2011012011 hasConcept C143998085 @default.
• W2011012011 hasConcept C2776309230 @default.
• W2011012011 hasConcept C2776694085 @default.
• W2011012011 hasConcept C2777938653 @default.
• W2011012011 hasConcept C2778336483 @default.
• W2011012011 hasConcept C2778461978 @default.
• W2011012011 hasConcept C2779338263 @default.
• W2011012011 hasConcept C2779380147 @default.
• W2011012011 hasConcept C2780653079 @default.
• W2011012011 hasConcept C2780931953 @default.
• W2011012011 hasConcept C71924100 @default.
• W2011012011 hasConcept C90924648 @default.
• W2011012011 hasConceptScore W2011012011C126322002 @default.
• W2011012011 hasConceptScore W2011012011C141071460 @default.
• W2011012011 hasConceptScore W2011012011C143998085 @default.
• W2011012011 hasConceptScore W2011012011C2776309230 @default.
• W2011012011 hasConceptScore W2011012011C2776694085 @default.
• W2011012011 hasConceptScore W2011012011C2777938653 @default.
• W2011012011 hasConceptScore W2011012011C2778336483 @default.
• W2011012011 hasConceptScore W2011012011C2778461978 @default.

• next